With RFK Jr. in Charge, Supplement Makers See Chance To Cash In

Last fall, before being named the senior U.S. health official, Robert F. Kennedy Jr. said the Trump administration would liberate Americans from the FDA’s “aggressive suppression” of vitamins, dietary supplements, and other substances — ending the federal agency’s “war on public health,” as he put it. In fact, the FDA can’t even require that supplements…

Read More

Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano

Sanofi’s equity investment in the new Orano Med entity comes a month after the pharmaceutical giant struck a €100 million deal to license a clinical-stage radiopharmaceutical developed for neuroendocrine tumors. Orano Med develops targeted cancer therapies based on lead-212, an alpha-emitting isotope. The post Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact…

Read More

Is Direct to Consumer (DTC) drug pricing an effective way to make drugs more affordable?

That is the topic of a recent BioSpace article titled “How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be?” A am quoted in the article as follows: While [direct-to-consumer] DTC has been a growing trend in biopharma for nearly two years now—Lilly launched LillyDirect in January 2024—the number of drugmakers looking to sell their…

Read More

Trump’s Push for U.S. Drug Manufacturing Expands to Pharma Ingredients With New Executive Order

The Trump administration is directing the Department of Health and Human Services to identify about 26 “critical medicines.” The federal government will stockpile active pharmaceutical ingredients for these products, which the administration contends will insulate the U.S. from foreign supplies while also encouraging more domestic API production. The post Trump’s Push for U.S. Drug Manufacturing…

Read More